Skip to main content

Table 1 Life-months gained

From: Long-term drug costs per life-month gained associated with first-line treatments for unresectable or metastatic melanoma

Melanoma treatment Life-months over all available follow-up Projected life-months for all drugs up to 7 yearsb
Life-monthsa Weibull Exponential Gompertz Log-normal
Ipilimumab 28.52 N/A N/A N/A N/A
Dabrafenib 21.47 26.51c 30.03 26.50 30.52
Trametinib 7.32 21.25c 26.53 16.94 36.69
Vemurafenib 13.00 14.28c 20.65 13.69 18.10
Dabrafenib + trametinib 16.78 24.55c 36.75 21.88 33.12
  1. aLife-months were calculated by the area under the curve of the Kaplan–Meier curves of overall survival for different drugs
  2. bParametric survival modeling was used to extrapolate the survival probabilities of dabrafenib, trametinib, vemurafenib, and dabrafenib + trametinib. Weibull model was used as the primary model (results denoted with c). Other parametric models (exponential, Gompertz, and log-normal) were used as sensitivity analysis